VEGF-A levels were determined by ELISA in serum samples of 18 responder (a) and 8 non-responder (b) melanoma patients before the start of therapy (T0), after two months of treatment (T2) and at disease progression (TP). This evidence concerns the gene VEGFA and melanoma.